Dernière mise à jour: Août 27, 2026
Comment les cellules souches sont-elles administrées pour la perte auditive?
En cas de perte auditive associée à un dysfonctionnement de l’oreille interne, infection antérieure, traumatisme, inflammation, ou certains troubles génétiques, mesenchymal stromal cell therapy is being investigated as a regenerative approach. The method of administration must always be selected individually after determining the precise cause and location of the hearing impairment.
The inner ear is a small, delicate, and anatomically difficult-to-access organ. Direct local injection into or near its structures is an invasive procedure that may damage residual hearing, the cochlea, the vestibular apparatus, or adjacent neural structures. Pour cette raison, systemic intravenous administration may be considered as a less invasive method of introducing cells into the circulation.
The organs and tissues of the human body are interconnected through the vascular system and microcirculation. Following intravenous administration, the cells enter the bloodstream and interact with biological signals produced by injured, inflamed, or stressed tissues. These signals may include chemokines, cytokines, molécules d'adhésion, et facteurs de croissance.
Mesenchymal stromal cells carry receptors capable of responding to some of these molecular signals. Ce processus est connu sous le nom référencement cellulaire ou chimiotaxie. Plutôt, molecular gradients may influence their adhesion, migration, and biological activity. research has identified signalling pathways such as SDF-1/CXCR4 as potentially relevant to cell migration toward injured cochlear tissues.
The possible therapeutic action is thought to depend mainly on paracrine signalling. Mesenchymal stromal cells release biologically active factors that may:
- modulate excessive inflammation;
- influence immune-cell activity;
- reduce cellular stress;
- support microvascular and endothelial function;
- stimulate survival and repair mechanisms in resident cells;
- promote a tissue environment more favourable to regeneration.
Depending on the underlying pathology, the affected structures may include cochlear hair cells, supporting cells, the stria vascularis, auditory neurons, the auditory nerve, or the inner-ear microcirculation. The potential cellular response may therefore differ considerably between hearing loss caused by inflammation or trauma and hearing loss resulting from an irreversible genetic defect.
Only very small numbers of endogenous progenitor cells normally circulate in peripheral blood, and their natural activity may be insufficient to reverse established chronic damage. In cell-therapy protocols, cells may therefore be isolated and expanded under controlled laboratory conditions to obtain a clinically defined dose. This process can take approximately seven days, selon la source des cellules, the manufacturing protocol, and the required quality-control testing.
An intravenous dose—for example, 10 million or more cells
Examen de cas scientifiques
Souhaitez-vous savoir si les programmes cliniques actuels, développements récents en recherche, ou des approches émergentes peuvent être adapté à votre situation individuelle?
Partagez votre question avec notre équipe de recherche scientifique et recevez informations axées sur les domaines de recherche en cours qui peuvent être pertinent pour votre cas.
- Examen des informations que vous fournissez
- Informations pertinentes sur la recherche et les programmes cliniques
- Une réponse claire et adaptée à votre situation
Aucune obligation. Votre question sera examinée de manière confidentielle.
Informations pédagogiques et de recherche uniquement. Ce service ne constituer un avis médical, diagnostic, ordonnance, ou un personnalisé recommandation de traitement.
